At Otsuka, one of our core values is humility—as a company, we unite to serve the needs of others before our own. Our approach to corporate social responsibility has grown naturally out of our commitment to put as much focus on our communities as we do on the medications that treat them.
Otsuka established the Sozosei Foundation in late 2019. The name Sozosei means “creativity” in Japanese. Otsuka’s Japanese heritage is manifest in the Foundation’s fundamental values and day-to-day operations.
To learn more about Sozosei please visit: www.SozoseiFoundation.org
Otsuka established the Sozosei Foundation in late 2019 to further support efforts in the areas of mental health, kidney diseases, disaster relief, and local community outreach. It is a US-based, private, charitable foundation committed to the health and well-being of our communities, promoting public awareness and education of healthcare issues, and supporting charitable and qualified exempt organizations. The Sozosei Foundation melds Otsuka’s deep experience in healthcare and our commitment to philanthropy and corporate social responsibility.
Otsuka-people are passionate about making an impact by taking part in initiatives that help build communities and support charitable organizations. Here are some of the organizations we support:
National Alliance on Mental Illness
American Foundation for Suicide Prevention
PKD (Polycystic Kidney Disease) Foundation
Mental Health America
National Council for Behavioral Health
Families for Depression Awareness
National Kidney Foundation
Our values extend to the local communities where our corporate operations are located. To assist in the fight against poverty and distribute food and aid to the people who need it most, we support and volunteer with local organizations in New Jersey and Maryland:
Trenton Soup Kitchen
Manna Food Center
Rise Against Hunger
With Otsuka offices all around the world, our reach extends outward to create global good. We lend support to these organizations:
All Hands and Hearts
Habitat for Humanity
Additionally, our parent company, Otsuka Holdings Co, Ltd, is a proud signatory to the United Nations Global Compact (UNGC). This initiative unites companies in the commitment to creating a sustainable and inclusive global economy that delivers lasting benefits to people, communities, and markets. As a signatory, Otsuka has pledged to adhere to the UNGC’s 10 principles
relating to human rights, nondiscriminatory labor practices, environmentally sound practices, and the prevention of corruption. These principles are aligned with Otsuka’s own values and our commitment to social responsibility, sustainability, and ethics.
Additionally, our parent company, Otsuka Holdings Co, Ltd, is a proud signatory to the United Nations Global Compact (UNGC). This initiative unites companies in the commitment to creating a sustainable and inclusive global economy that delivers lasting benefits to people, communities, and markets. As a signatory, Otsuka has pledged to adhere to the UNGC’s 10 principles relating to human rights, nondiscriminatory labor practices, environmentally sound practices, and the prevention of corruption. These principles are aligned with Otsuka’s own values and our commitment to social responsibility, sustainability, and ethics.
Independent Medical Education for Healthcare Professionals (IME)
We are committed to funding innovative education and independent studies that support healthcare professionals in their learning and development.
To be eligible for consideration, the program must:
Advance the systems-based practice of medicine
Improve the accessibility, quality, and delivery of patient care
Deliver education solutions that reinforce learning and change in HCPs through the rigorous application of adult learning principles and scientific evidence
Investigator-sponsored Studies (ISS)
In our dedication to serving unmet medical needs, we support independent investigator-sponsored studies that have the potential to impact the disease of interest. Otsuka may provide financial support and/or study drugs, but is not the study sponsor and assumes no sponsor obligations.
The advancement of healthier lives begins with our own fair, open, and honest community. Our comprehensive compliance program reflects our commitment to conducting business honestly, ethically, and in compliance with the laws and regulations where we operate. Otsuka innovates with integrity, never losing sight of the trust that others have placed in us. Compliance is the responsibility of every colleague, and managers play a crucial role in setting the example for compliant behavior and practices.
At Otsuka, we treat one another with dignity and respect. As a caring corporate citizen, we take responsibility for our actions in the local, national, and international communities where we operate.
In accordance with Vermont law 18 V.S.A. § 4633, marketers of certain pharmaceutical products are required to disclose to Vermont doctors and other prescribers average wholesale price (AWP) information for drugs they market as well as the AWPs of other drugs in the same therapeutic class.
Listings within these charts do not imply that products are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved prescribing information for such determinations.
The AWP information identified on the disclosure forms is based on third-party published data and may not be reflective of prices actually charged to or paid for by any customer.
Our Code, Policies and Procedures
The US Code of Ethics and Professional Conduct (the “Code”) describes Otsuka’s fundamental values and summarizes the policies and legal requirements that apply to our business. The Code is supported by policies and procedures governing our
general business activities as well as those activities related to marketing and sales of our pharmaceutical products and interactions with healthcare professionals.
Effective Training, Communication and Continuing Advice
Otsuka provides Compliance and Ethics learning programs for all employees and relevant third party suppliers. General compliance training includes understanding our Compliance Program, the Code, policies and standard operating procedures. Otsuka provides training specific to federal healthcare program and Food & Drug Administration (“FDA”) requirements related to promotional and product-related functions, training to prevent
fraud and corruption, as well as training regarding Good Manufacturing and Good Clinical Practices. The Ethics & Compliance Group also works with its business partners throughout the Company to provide continuing advice on compliance and quality matters. Finally, we ensure that our education and training programs are effective by applying adult learning principles.
Open Lines of Communication
Otsuka has a Speak-Up policy, which requires all employees to speak up when they have a question regarding a Company policy or procedure, or when they are faced with an ethical dilemma. All employees should feel comfortable requesting guidance from
the Company, and are encouraged to discuss any questions, concerns, complaints or suggestions with their supervisor, Human Resources, Ethics & Compliance (“E&C”), or Legal Affairs.
Confidential Reporting and Internal Investigations; Prompt Response to Problems and Corrective Actions
Our Code requires employees to report any known or suspected violations of company policies to their supervisor or to the Chief Compliance Officer (“CCO”). Additionally, Otsuka’s policies strictly prohibit any adverse action against any person who, in good faith, reports known or suspected compliance issues. The Company has established a toll-free telephone number, 1-800-363-5670, for reporting violations or possible violations of the Compliance Program or other company policies. In the event the Company becomes aware of any suspected noncompliance
with the Compliance Program or the relevant policies and procedures, through either routine monitoring or a reported violation, the Chief Compliance Officer will investigate the circumstances surrounding the suspected noncompliance to determine whether a violation has occurred. If the investigation reveals a violation, the Company will take appropriate corrective action, which may involve disciplinary actions up to and including termination.
Incentives, Publicized Disciplinary Guidelines and Disciplinary Measures
All Otsuka colleagues are constantly evaluated on their adherence to the principles expressed in our Code. The potential disciplinary actions that can be taken when employees are found to have violated Company policies, or have failed to report
violations, of which they were aware, are explained in the Code. Our Code also highlights the heightened responsibilities of supervisors with regard to compliance.
Oversight, Autonomy and Resources; Compliance Officer and Committees
The CCO is charged with monitoring the Compliance Program, and serves as the primary contact for issues relating to compliance with the Program. The CCO reports directly to the Chief Executive Officer (“CEO”), and provides periodic reports to
the Board of Directors and the Audit Committee of the Board of Directors. The CCO also serves as the Chair of the Compliance Committee, which is composed of senior management personnel and provides oversight and guidance for compliance activities.
Continuous Improvement, Periodic Testing and Review Through Internal Auditing and Monitoring
Otsuka’s Compliance Program is continuously evolving, incorporating learning from internal auditing and monitoring, as well as external trends and developments. Each year, a compliance auditing and monitoring plan is developed to test the implementation and effectiveness of compliance policies and
procedures, utilizing both risk-based and random sampling techniques. Results of each audit and monitoring activity are shared with the appropriate Business Owners and the Compliance Committee to assess any needed follow-up actions.
Otsuka’s Compliance Program utilizes a risk-based approach to focus resources. We routinely assess the risks inherent with new programs and concepts, and we consider the level of risk when
designing audit and monitoring plans. Additionally, Otsuka regularly seeks a third-party view of its operations, commissioning risk assessments from external parties.
Third Party Due Diligence and Payments
All third-parties with whom Otsuka does business are subject to screening to ensure that they do not present additional risk to the Company’s business or reputation. Otsuka’s contracts with third-
parties include compliance training requirements and assurances, audit rights, and other provisions depending on the type of service provided by the third-party.
Mergers and Acquisitions: Pre-acquisition Due Diligence and Post-acquisition Integration
Otsuka conducts due diligence on all potential acquisition targets, as well as on all companies with whom it enters into joint promotion and development agreements. This due diligence includes, but is not limited to, an assessment of the compliance program, policies and procedures, and internal controls. After
acquisition, Otsuka will ensure a thorough integration, ensuring that new colleagues understand its commitment to compliance and our Compliance Program, and that internal controls extend to the acquisition target.